Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Keros Therapeutics, Inc.KROS · Entity 6242 | 10% owner | April 13, 2020 | April 13, 2020 |
| Odysight.ai Inc.ODYS · Entity 7081 | Director · 10% owner | August 20, 2026 | August 24, 2026 |
| Sol-Gel Technologies Ltd.SLGL · Entity 1558 | Director · Chairman of Board and CEO · 10% owner | March 18, 2026 | March 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Keros Therapeutics, Inc.
Report date April 13, 2020 · Filed April 13, 2020
Jointly reported with Arkin Bio Ventures Limited Partnership, Arkin Bio Venture Partners Ltd.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,013,102 |
Last balance in matching sequence
After 2020-04-13 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2020-04-13 · Conversion · Acquired 1,382,295 · Balance 1,382,295 F1: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F2: The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Venture Partners Ltd.. Row 2 · 2020-04-13 · Conversion · Acquired 343,270 · Balance 1,725,565 F1: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F2: The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Venture Partners Ltd.. Row 3 · 2020-04-13 · Conversion · Acquired 167,537 · Balance 1,893,102 F1: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F2: The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Venture Partners Ltd.. Row 4 · 2020-04-13 · Purchase · Acquired 120,000 · Balance 2,013,102 F2: The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Venture Partners Ltd.. |
| Series A Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-04-13 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-04-13 · Conversion · Disposed 1,382,295 · Balance 0 F1: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F2: The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Venture Partners Ltd.. |
| Series B-1 Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-04-13 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-04-13 · Conversion · Disposed 343,270 · Balance 0 F1: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F2: The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Venture Partners Ltd.. |
| Series C Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-04-13 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-04-13 · Conversion · Disposed 167,537 · Balance 0 F1: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F2: The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Venture Partners Ltd.. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date.
F2: The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Venture Partners Ltd..
Odysight.ai Inc.
Report date August 20, 2026 · Filed August 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectHeld through M.Arkin (1999) Ltd. | 4,084,143 |
Reported balance
After 2026-08-20 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-08-20 · Purchase · Acquired 1,125,000 · Balance 4,084,143 F2: On August 20, 2026, the Reporting Person acquired 1,125,000 shares of common stock in the Issuer's underwritten public offering of shares of common stock for an offering price of $3.20 per share of common stock. |
| Common StockSEC Table I · non-derivative | IndirectHeld through Phoenix Insurance Company Ltd. | 2,624,838 |
Reported balance
Holding disclosure · report date 2026-08-20 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 2,624,838 F1: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only. |
Filing footnotes · ownership attribution and instrument terms
F1: No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.
F2: On August 20, 2026, the Reporting Person acquired 1,125,000 shares of common stock in the Issuer's underwritten public offering of shares of common stock for an offering price of $3.20 per share of common stock.
Sol-Gel Technologies Ltd.
Report date March 18, 2026 · Filed March 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 143,257 |
Reported balance
Holding disclosure · report date 2026-03-18 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 143,257 F1: Ordinary shares, NIS 1.00 par value per share. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy M. Arkin Dermatology Ltd. | 1,606,856 |
Reported balance
Holding disclosure · report date 2026-03-18 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,606,856 F1: Ordinary shares, NIS 1.00 par value per share. F2: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $58.50 · Expires 2028-01-27 | IndirectBy M. Arkin Dermatology Ltd. | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F1: Ordinary shares, NIS 1.00 par value per share. F2: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Ordinary shares, NIS 1.00 par value per share.
F2: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Werewolf Therapeutics, Inc.
Report date May 04, 2021 · Filed May 04, 2021
Jointly reported with Arkin Bio Ventures 2 L.P., Arkin Bio Ventures GPGP Ltd.
Section 16 reporting ended · disclosed 2021-05-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,046,634 |
Last balance in matching sequence
After 2021-05-04 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2021-05-04 · Conversion · Acquired 1,235,917 · Balance 1,235,917 F1: On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The securities are held by Arkin Bio Ventures 2 L.P. (the "Fund"). The general partner of the Fund is Arkin Bio Ventures GP, the general partner of which is Arkin Bio Ventures GPGP Ltd. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Ventures GPGP Ltd. As a result, each of Arkin Bio Ventures GP, Arkin Bio Ventures GPGP Ltd. and Mr. Arkin may be deemed to share voting and investment power with respect to the shares held by the Fund. Row 2 · 2021-05-04 · Conversion · Acquired 410,717 · Balance 1,646,634 F3: On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The securities are held by Arkin Bio Ventures 2 L.P. (the "Fund"). The general partner of the Fund is Arkin Bio Ventures GP, the general partner of which is Arkin Bio Ventures GPGP Ltd. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Ventures GPGP Ltd. As a result, each of Arkin Bio Ventures GP, Arkin Bio Ventures GPGP Ltd. and Mr. Arkin may be deemed to share voting and investment power with respect to the shares held by the Fund. Row 3 · 2021-05-04 · Purchase · Acquired 400,000 · Balance 2,046,634 F2: The securities are held by Arkin Bio Ventures 2 L.P. (the "Fund"). The general partner of the Fund is Arkin Bio Ventures GP, the general partner of which is Arkin Bio Ventures GPGP Ltd. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Ventures GPGP Ltd. As a result, each of Arkin Bio Ventures GP, Arkin Bio Ventures GPGP Ltd. and Mr. Arkin may be deemed to share voting and investment power with respect to the shares held by the Fund. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2021-05-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-05-04 · Conversion · Disposed 10,714,284 · Balance 0 F1: On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The securities are held by Arkin Bio Ventures 2 L.P. (the "Fund"). The general partner of the Fund is Arkin Bio Ventures GP, the general partner of which is Arkin Bio Ventures GPGP Ltd. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Ventures GPGP Ltd. As a result, each of Arkin Bio Ventures GP, Arkin Bio Ventures GPGP Ltd. and Mr. Arkin may be deemed to share voting and investment power with respect to the shares held by the Fund. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2021-05-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-05-04 · Conversion · Disposed 3,560,551 · Balance 0 F3: On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The securities are held by Arkin Bio Ventures 2 L.P. (the "Fund"). The general partner of the Fund is Arkin Bio Ventures GP, the general partner of which is Arkin Bio Ventures GPGP Ltd. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Ventures GPGP Ltd. As a result, each of Arkin Bio Ventures GP, Arkin Bio Ventures GPGP Ltd. and Mr. Arkin may be deemed to share voting and investment power with respect to the shares held by the Fund. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
F2: The securities are held by Arkin Bio Ventures 2 L.P. (the "Fund"). The general partner of the Fund is Arkin Bio Ventures GP, the general partner of which is Arkin Bio Ventures GPGP Ltd. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Ventures GPGP Ltd. As a result, each of Arkin Bio Ventures GP, Arkin Bio Ventures GPGP Ltd. and Mr. Arkin may be deemed to share voting and investment power with respect to the shares held by the Fund.
F3: On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 20, 2026 Filed Aug 24, 2026 20:05 UTC | Odysight.ai Inc. ODYS · Entity 7081 | PurchaseCommon Stock | 1,125,000 | $3.20 | $3,600,000.00 |
DisclosureSEC source: 0001493152-26-039861 · ownership.xml · nonDerivative · entry 2 Arkin Moshe · CIK 0001321178 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Held through M.Arkin (1999) Ltd. Disclosed balance after: 4,084,143 F2 · shares: On August 20, 2026, the Reporting Person acquired 1,125,000 shares of common stock in the Issuer's underwritten public offering of shares of common stock for an offering price of $3.20 per share of common stock. Read SEC document |
| March 25, 2026 Filed Mar 27, 2026 20:05 UTC | Odysight.ai Inc. ODYS · Entity 7081 | Exercise / conversionWarrants to purchase common stock · Derivative | 2,352,941 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001493152-26-013193 · ownership.xml · derivative · entry 4 Arkin Moshe · CIK 0001321178 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Held through Phoenix Insurance Company Ltd. Disclosed balance after: 0 Underlying: Common Stock · 2,352,941 shares Expires 2026-03-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The cashless exercise of the warrant to purchase common stock was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Board of Directors. Read SEC document |
| March 25, 2026 Filed Mar 27, 2026 20:05 UTC | Odysight.ai Inc. ODYS · Entity 7081 | Tax withholdingCommon Stock | 2,081,044 | $5.50 | $11,445,742.00 |
DisclosureSEC source: 0001493152-26-013193 · ownership.xml · nonDerivative · entry 2 Arkin Moshe · CIK 0001321178 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Held through Phoenix Insurance Company Ltd. Disclosed balance after: 2,624,838 F2 · shares: On March 25, 2026, Phoenix Insurance Company Ltd. exercised a warrant to purchase 2,352,941 shares of the Issuer's common stock for $5.50 per share. The Reporting Person paid the exercise price on a cashless basis, resulting in the Issuer withholding 2,081,044 of the warrant shares to pay the exercise price and issuing to the Reporting Person the remaining 271,897 shares. Read SEC document |
| March 25, 2026 Filed Mar 27, 2026 20:05 UTC | Odysight.ai Inc. ODYS · Entity 7081 | Exercise / conversionCommon Stock | 2,352,941 | $5.50 | $12,941,175.50 |
DisclosureSEC source: 0001493152-26-013193 · ownership.xml · nonDerivative · entry 1 Arkin Moshe · CIK 0001321178 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Held through Phoenix Insurance Company Ltd. Disclosed balance after: 4,705,882 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The cashless exercise of the warrant to purchase common stock was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Board of Directors. F2 · shares: On March 25, 2026, Phoenix Insurance Company Ltd. exercised a warrant to purchase 2,352,941 shares of the Issuer's common stock for $5.50 per share. The Reporting Person paid the exercise price on a cashless basis, resulting in the Issuer withholding 2,081,044 of the warrant shares to pay the exercise price and issuing to the Reporting Person the remaining 271,897 shares. Read SEC document |
| May 04, 2021 Filed May 4, 2021 20:31 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | ConversionSeries B Preferred Stock · Derivative | 3,560,551 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-018121 · doc4.xml · derivative · entry 5 Arkin Bio Ventures 2 L.P. · CIK 0001858705 · 10% owner Arkin Bio Ventures GPGP Ltd. · CIK 0001858707 · 10% owner Arkin Moshe · CIK 0001321178 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 410,717 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3 · derivative.exercise_date: On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3 · derivative.expiration_date: On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.nature: The securities are held by Arkin Bio Ventures 2 L.P. (the "Fund"). The general partner of the Fund is Arkin Bio Ventures GP, the general partner of which is Arkin Bio Ventures GPGP Ltd. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Ventures GPGP Ltd. As a result, each of Arkin Bio Ventures GP, Arkin Bio Ventures GPGP Ltd. and Mr. Arkin may be deemed to share voting and investment power with respect to the shares held by the Fund. Read SEC document |
| May 04, 2021 Filed May 4, 2021 20:31 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | ConversionSeries A Preferred Stock · Derivative | 10,714,284 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-018121 · doc4.xml · derivative · entry 4 Arkin Bio Ventures 2 L.P. · CIK 0001858705 · 10% owner Arkin Bio Ventures GPGP Ltd. · CIK 0001858707 · 10% owner Arkin Moshe · CIK 0001321178 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,235,917 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.nature: The securities are held by Arkin Bio Ventures 2 L.P. (the "Fund"). The general partner of the Fund is Arkin Bio Ventures GP, the general partner of which is Arkin Bio Ventures GPGP Ltd. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Ventures GPGP Ltd. As a result, each of Arkin Bio Ventures GP, Arkin Bio Ventures GPGP Ltd. and Mr. Arkin may be deemed to share voting and investment power with respect to the shares held by the Fund. Read SEC document |
| May 04, 2021 Filed May 4, 2021 20:31 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | PurchaseCommon Stock | 400,000 | $16.00 | $6,400,000.00 |
DisclosureSEC source: 0000899243-21-018121 · doc4.xml · nonDerivative · entry 3 Arkin Bio Ventures 2 L.P. · CIK 0001858705 · 10% owner Arkin Bio Ventures GPGP Ltd. · CIK 0001858707 · 10% owner Arkin Moshe · CIK 0001321178 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,046,634 F2 · ownership.nature: The securities are held by Arkin Bio Ventures 2 L.P. (the "Fund"). The general partner of the Fund is Arkin Bio Ventures GP, the general partner of which is Arkin Bio Ventures GPGP Ltd. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Ventures GPGP Ltd. As a result, each of Arkin Bio Ventures GP, Arkin Bio Ventures GPGP Ltd. and Mr. Arkin may be deemed to share voting and investment power with respect to the shares held by the Fund. Read SEC document |
| May 04, 2021 Filed May 4, 2021 20:31 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | ConversionCommon Stock | 410,717 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-018121 · doc4.xml · nonDerivative · entry 2 Arkin Bio Ventures 2 L.P. · CIK 0001858705 · 10% owner Arkin Bio Ventures GPGP Ltd. · CIK 0001858707 · 10% owner Arkin Moshe · CIK 0001321178 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,646,634 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.nature: The securities are held by Arkin Bio Ventures 2 L.P. (the "Fund"). The general partner of the Fund is Arkin Bio Ventures GP, the general partner of which is Arkin Bio Ventures GPGP Ltd. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Ventures GPGP Ltd. As a result, each of Arkin Bio Ventures GP, Arkin Bio Ventures GPGP Ltd. and Mr. Arkin may be deemed to share voting and investment power with respect to the shares held by the Fund. Read SEC document |
| May 04, 2021 Filed May 4, 2021 20:31 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | ConversionCommon Stock | 1,235,917 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-018121 · doc4.xml · nonDerivative · entry 1 Arkin Bio Ventures 2 L.P. · CIK 0001858705 · 10% owner Arkin Bio Ventures GPGP Ltd. · CIK 0001858707 · 10% owner Arkin Moshe · CIK 0001321178 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,235,917 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.nature: The securities are held by Arkin Bio Ventures 2 L.P. (the "Fund"). The general partner of the Fund is Arkin Bio Ventures GP, the general partner of which is Arkin Bio Ventures GPGP Ltd. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Ventures GPGP Ltd. As a result, each of Arkin Bio Ventures GP, Arkin Bio Ventures GPGP Ltd. and Mr. Arkin may be deemed to share voting and investment power with respect to the shares held by the Fund. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 17:29 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionSeries C Preferred Stock · Derivative | 167,537 | $0.00 | $0.00 |
DisclosureSEC source: 0001178913-20-001105 · zk2024260.xml · derivative · entry 7 Arkin Bio Ventures Limited Partnership · CIK 0001808348 · 10% owner Arkin Bio Venture Partners Ltd. · CIK 0001808349 · 10% owner Arkin Moshe · CIK 0001321178 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 167,537 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F2 · ownership.direct: The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Venture Partners Ltd.. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 17:29 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionSeries B-1 Preferred Stock · Derivative | 343,270 | $0.00 | $0.00 |
DisclosureSEC source: 0001178913-20-001105 · zk2024260.xml · derivative · entry 6 Arkin Bio Ventures Limited Partnership · CIK 0001808348 · 10% owner Arkin Bio Venture Partners Ltd. · CIK 0001808349 · 10% owner Arkin Moshe · CIK 0001321178 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 343,270 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F2 · ownership.direct: The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Venture Partners Ltd.. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 17:29 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionSeries A Preferred Stock · Derivative | 1,382,295 | $0.00 | $0.00 |
DisclosureSEC source: 0001178913-20-001105 · zk2024260.xml · derivative · entry 5 Arkin Bio Ventures Limited Partnership · CIK 0001808348 · 10% owner Arkin Bio Venture Partners Ltd. · CIK 0001808349 · 10% owner Arkin Moshe · CIK 0001321178 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,382,295 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F2 · ownership.direct: The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Venture Partners Ltd.. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 17:29 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | PurchaseCommon Stock | 120,000 | $16.00 | $1,920,000.00 |
DisclosureSEC source: 0001178913-20-001105 · zk2024260.xml · nonDerivative · entry 4 Arkin Bio Ventures Limited Partnership · CIK 0001808348 · 10% owner Arkin Bio Venture Partners Ltd. · CIK 0001808349 · 10% owner Arkin Moshe · CIK 0001321178 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,013,102 F2 · ownership.direct: The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Venture Partners Ltd.. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 17:29 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionCommon Stock | 167,537 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001178913-20-001105 · zk2024260.xml · nonDerivative · entry 3 Arkin Bio Ventures Limited Partnership · CIK 0001808348 · 10% owner Arkin Bio Venture Partners Ltd. · CIK 0001808349 · 10% owner Arkin Moshe · CIK 0001321178 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,893,102 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F2 · ownership.direct: The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Venture Partners Ltd.. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 17:29 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionCommon Stock | 343,270 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001178913-20-001105 · zk2024260.xml · nonDerivative · entry 2 Arkin Bio Ventures Limited Partnership · CIK 0001808348 · 10% owner Arkin Bio Venture Partners Ltd. · CIK 0001808349 · 10% owner Arkin Moshe · CIK 0001321178 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,725,565 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F2 · ownership.direct: The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Venture Partners Ltd.. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 17:29 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | ConversionCommon Stock | 1,382,295 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001178913-20-001105 · zk2024260.xml · nonDerivative · entry 1 Arkin Bio Ventures Limited Partnership · CIK 0001808348 · 10% owner Arkin Bio Venture Partners Ltd. · CIK 0001808349 · 10% owner Arkin Moshe · CIK 0001321178 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,382,295 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date. F2 · ownership.direct: The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Venture Partners Ltd.. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.